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The KDIGO guideline for glomerulonephritis is designed to
assist health-care providers in treating patients with
glomerular diseases. A guideline is not a set of rules but is
intended to allow the practitioner to make an informed
decision based on the available evidence. Due to its general
nature and the variability of strength of the available studies,
it is often difficult to directly apply a guideline to the care of
an individual patient. This commonly relates to the limited
generalizability of the evidence, i.e., does not cover every
clinical scenario. To underscore this point, we have
introduced within the context of the glomerulonephritis
guideline cases with specific features to illustrate the
constant need for clinical judgment. These vignettes are
intended to demonstrate how the best treatment plans
should be individualized and take into account patient
preference and clinical acumen, as well as the best available
evidence.
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Clinical practice guidelines (CPGs) have become a mainstay
in clinical practice and have encompassed every single branch
of medicine. As defined by the Institute of Medicine, clinical
guidelines are ‘systematically developed statements to assist
practitioner and patient decisions about appropriate health
care for specific clinical circumstances’.1 The potential
benefits of CPGs are many. By providing clear recommenda-
tion based on current evidence, CPGs can improve the
quality of clinical decisions. Evidence-based guidelines
support interventions that are of proven benefit while
documenting the quality of the supporting data. Further,
interventions unsupported by good science are also reviewed
and call attention to ineffective (or even dangerous) practices.
On the flip side, there is also the possibility that CPGs could
have negative consequences.2 In the situation in which only a
few studies are of high enough quality, many recommenda-
tions made by guideline committees are subjective and
‘opinion-based’. Further, despite good-quality data, a recom-
mendation may not be suitable for a particular patient.
Finally, applications of nonmedical values combined with
intense pressures on health-care provision can create an
environment for guideline misuse.3
Although CPGs have been shown to improve the quality
of care,4 whether they achieve this in daily practice is less clear.2
In an analysis of 59 CPG evaluations covering a wide range
of clinical activities, all but 4 detected statistically significant
improvements in the process of medical care. Moreover, all
except 2 of the 11 evaluations that also measured the outcome
of care reported significant improvements in outcome.4 Guide-
lines that are likely to change medical practice have a few
characteristics in common. First, they are likely to be developed
internally by the very physicians who are going to use them.
Second, appropriate development, dissemination, and imple-
mentation strategies are adopted during their introduction.
Last, implementation strategies that are operative within the
doctor–patient consultation are more likely to be effective.5
DEVELOPMENT OF THE KDIGO GUIDELINE FOR GN
Guideline development is a lengthy process (over 2–3 years).
A working group was created consisting of clinical experts
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in the field of glomerular disease and an ‘evidence review
team’ who are experts in the field of guideline develop-
ment (using techniques including systematic reviews and
meta analyses). The working group formulated recommen-
dations related to a specific question or topic. Each set
of recommendations was followed by a ‘rationale’ section,
which summarizes the evidence and the reasoning for each
recommendation and explains why specific wording was
chosen.
WHY DO WE NEED GN GUIDELINES?
The therapeutic decisions of the physician are based on the
continuing need to balance the risks and benefits of
treatment. Ideally, one seeks a treatment regimen that
reduces immunosuppressive therapy exposure to the mini-
mum, minimizes immediate morbidity (e.g., achieving
remission of nephrotic syndrome), and prevents disease
progression. However, physicians must also recognize that
more prolonged treatment may be required, given the long-
term threat that failure to prevent end-stage renal disease will
shorten life expectancy and may only delay prolonged
immunosuppressive drug exposure that would be required
after kidney transplantation. The focus in the management of
chronic patterns of glomerular disease has shifted from cure
to control, with the recognition of the short- and long-term
benefits of a reduction in proteinuria and the concept of
‘maintenance’ therapy, which is intended to avoid relapses.
This paradigm has translated into the use of more extended
(or repeated) treatment regimens with the possibility of more
toxic drug exposure.
The Kidney Disease: Improving Global Outcomes
(KDIGO) guideline is intended to provide the practitioner
with information to make an informed decision based on the
data available for most of the common glomerular diseases.
The critical point we are making here is that CPGs such as
those of KDIGO are intended to provide guidance rather
than a strict set of rules. The overarching purpose of the
recommendations is to assist in decision-making and not
provide a ‘cookie-cutter’ approach to management. This is
because a guideline recommendation cannot account for all
possible variations of patients, providers, and system factors.
Thus, each health-care provider needs to assess the appro-
priateness of a particular recommendation or suggestion in a
specific context. By using examples of glomerular disease, we
will attempt to underline the relevance of the complex
interaction of factors, which often impacts on treatment
decisions in these disorders.
APPLICATION OF THE KDIGO GUIDELINES FOR GN: CLINICAL
EXAMPLES
1. Focal segmental glomerulosclerosis
Guideline 6.1: Initial evaluation
6.1.1: Thorough evaluation should be undertaken to
exclude secondary forms of focal segmental glomer-
ulosclerosis (FSGS) (not graded).
6.1.2: Genetic testing should not be performed routinely
(not graded).
A 30-year-old male patient of African heritage was referred
for workup of proteinuria discovered during a routine
physical examination. The patient was on no medications.
There was no family history of any kidney disease, but many
family members were diabetic and hypertensive. His last
examination 3 years ago was normal (including a negative
urine analysis). On examination, his BMI was 35 kg/m2, BP
was 150/88, and he had 1þ pitting pedal edema. Laboratory
examination revealed a serum creatinine (SCr) level of
1.4mg/dl, serum albumin of 3.5 g/dl, total cholesterol of
282mg/dl and 24-h urine protein of 8.2 g. His glycosylated
hemoglobin level was 6.3%; two of his siblings and both
parents were diabetic.
A kidney biopsy showed 22 normal-sized glomeruli,
2 globally sclerosed, and 3 showing scarring limited to the
hilar region of the glomerulus (Hilar variant of FSGS).
Immunofluorescence showed C3 and IgM in the areas of
sclerosis and electron micrograph showed 70% foot process
effacement, no electron-dense deposits, or tubuloreticular
inclusions. The HIV virus test was negative.
One of the most challenging areas in FSGS is to deter-
mine whether the patient has secondary forms of FSGS
where immunosuppressives might not be helpful. In this
patient, there are many clues that might indicate a secondary
(maldaptive/hyperfiltration) form of FSGS. The presence
of obesity, a relatively normal serum albumin, and the
hilar histological variant are suggestive of secondary
FSGS.6,7 However, a lack of glomerulomegaly and the
extensive foot process effacement might indicate the
‘primary’ form.8
In such a patient, the prudent approach would be to start
with a conservative management strategy with aggressive BP
control, weight loss, and renin–angiotensin–aldosterone
system inhibition. Genetic testing is not indicated in view
of negative family history, as the yield will be low and
currently, aside from the very early-onset mutations such as
nephrin, it is not clear that the presence of genetic mutations
will correlate with the failure to respond to standard
immunosuppressive therapy.
The patient was started on angiotensin-converting-
enzyme inhibitor (ACEi) and a thiazide diuretic. BP levels
were controlled to 125/80 or lower. However, edema
persisted, requiring the addition of furosemide. Proteinur-
ia did not improve and remained in the 8–10-g/day range
with serum albumin levels between 3.0 and –3.5 g/dl.
Cholesterol levels were controlled with the addition of
a statin.
Guideline 6.2: Initial treatment of FSGS
6.2.1: We recommend that corticosteroid and immuno-
suppressive therapy be considered only in idiopathic
FSGS associated clinically with features of the
nephrotic syndrome (1C).
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6.2.2: We suggest prednisone or prednisolone be given at a
daily single dose of 1mg/kg (maximum 80mg) or an
alternate-day dose of 2mg/kg (a maximum dose of
120mg) (2C).
6.2.3: We suggest the initial high dose of corticosteroids be
given for a minimum of 4 weeks; continue high-dose
corticosteroids up to a maximum of 16 weeks, as
tolerated, or until complete remission has been
achieved, whichever is earlier (2D).
6.2.4: We suggest corticosteroids be tapered slowly over a
period of 6 months after achieving complete remis-
sion (2D).
6.2.5: We suggest calcineurin inhibitors (CNIs) be consid-
ered as first-line therapy for patients with relative
contraindications or intolerance to high-dose cortico-
steroids (e.g., uncontrolled diabetes, psychiatric con-
ditions, severe osteoporosis) (2D).
The conundrum here is that there are features of the
nephrotic syndrome, but the patient might have a secondary
form of FSGS. The patient is experiencing persistent high-
grade proteinuria (suggesting an adverse prognosis). A lack of
response to the renin–angiotensin–aldosterone system inhibi-
tion again points away from secondary FSGS.9 At this point,
we are looking at an immunosuppression strategy; KDIGO
recommends corticosteroids as first-line therapy. However,
in view of this patient’s obesity, strong family history of
diabetes, and an elevated HbA1c at presentation, we might
choose a CNI as alternate first-line therapy. Cyclosporine
might be preferred over tacrolimus in view of a lesser
tendency to precipitate diabetes.10
The patient was started on a regimen of modified
cyclosporine at a dose of 2mg/kg/day twice daily to target
trough levels between 125 and 150 ng/ml. Two months later,
urine protein had dropped to 2.2 g/day. The medication was
continued for 12 months. A slow taper off the medication
over a further 6 months was associated with continued partial
remission of proteinuria. Cyclosporine was discontinued
after a total of 36 months of therapy, with proteinuria in the
1–2-g/day range. The patient continued on treatment with
ACEi and antihypertensives.
Does the response to CNIs suggest a primary FSGS? CNIs
have been reported to lower proteinuria in genetic mutations
associated with NPHS2 mutation,11 Alport syndrome.12 This
nonimmunological reduction of proteinuria is thought to be
due to a reduction of permselectivity of proteins at the
glomerular barrier,13 and more recently the finding that CNI
prevent dephosphorylation of the podocyte protein synapto-
podin, which is required for maintenance of the actin
cytoskeleton in the podocyte.14 Thus, it is entirely possible
that CNI use may be associated with nonimmunological
proteinuria reduction from local effects on the glomerular
capillary barrier, although in general these conditions are not
associated with this degree of proteinuria. However, the
eventual achievement of partial remission status will improve
the renal prognosis in the future, and this was the ultimate
goal of therapy.
To sum up, we have illustrated with the case above that
there are nuances in FSGS patients that might make the literal
interpretation of a guideline difficult (and sometimes
inappropriate). The guideline does not spell out how one
differentiates primary from secondary FSGS. For example,
if the patient had lower amounts of proteinuria and a
completely normal serum albumin and less foot process
effacement (say 30%), then the chances of a secondary form
of FSGS become higher and the practitioner might avoid
the use of an immunosuppressive drug. In this case, the
parameters were more in favor of what one would lean
toward the primary or ‘idiopathic’ from FSGS (low albumin,
higher levels of proteinuria, high percentage of foot process
effacement) rather than the ‘secondary’ forms (normal
albumin, glomerulomegaly, lower percentage of foot process
effacement) and thus immunosuppressive therapy would be
indicated. The choice of initial immunosuppression was
determined by the presence of obesity and diabetes risk, and
a CNI was chosen over corticosteroids.
2. Lupus nephritis
Guideline 12.3: Class III lupus nephritis (LN; focal LN) and
class IV LN (diffuse LN)—initial therapy
12.3.1: We recommend initial therapy with corticosteroids
(1A), combined with either cyclophosphamide
(CYC) (1B) or mycophenolate mofetil (MMF) (1B).
12.3.2: We suggest that if patients have worsening LN
(rising SCr level, worsening proteinuria) during the
first 3 months of treatment, a change be made to an
alternative recommended initial therapy, or a repeat
kidney biopsy be performed to guide further
treatment (2D).
A 22-year-old Caucasian female patient with known
systemic lupus erythematosus, who presented with protei-
nuria of 3.8 g/day, 20–25 red blood cells per high-power field,
and SCr level of 1.3mg/dl (baseline 0.7mg/dl), was diagnosed
with ISN/RPS Class IV-S (A) LN on renal biopsy, with 75%
of glomeruli involved and the majority of these glomeruli
showing endocapillary proliferation. Immunofluorescence
microscopy showed ‘full-house’ staining with IgG, IgM, C3,
C1q, kappa, and lambda. A few areas of fibrinoid necrosis
were seen, with 2 of 22 glomeruli showing noncircumfer-
ential crescents. In addition, there was an infiltrate composed
of lymphocytes and macrophages occupying 30% of the
interstitium.
At first look, this patient had severe LN with class IV
lesions. Are there subtleties in the biopsy that might change
the approach to therapy? How do the renal biopsy findings
play into treatment decisions? There are three notable
findings in this patient, which may adversely impact renal
prognosis and, subsequently, treatment. First, published
observations initially suggested that Class IV-G (typically
associated with florid ‘wire loop’ deposits) had a better
prognosis than Class IV-S (more endocapillary proliferation
and fibrinoid necrosis). This was not borne out by later
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studies as reviewed by Markowitz and D’Agati.15 Second,
the presence of areas of fibrinoid necrosis is suspicious for
anti-neutrophil cytoplasmic antibody (ANCA)-associated
vasculitis,16 and ANCA titers should be requested. Last,
the presence of an interstitial infiltrate is recognized to
be associated with a worse prognosis.17 The guideline does
not discuss aspects of renal pathology with respect to
treatment, mainly because data on whether aggressive
treatment modifies the prognosis are not available. How-
ever, impaired creatinine at presentation, in conjunction
with these pathological features, gives us the overall
impression that the disease is aggressive. There is a real
paucity of data with respect to the choice of induction
therapy in the more aggressive forms of LN. A comparison
of CYC versus MMF was reported in a small retrospective
study from Korea, and MMF was associated with worse
long-term outcomes despite similar remission rates when
compared with CYC.18 Given a relative paucity of long-term
efficacy data on MMF and the possibility that MMF may be
inferior, one might choose CYC as an induction agent in this
patient.
The choice of induction therapy (MMF vs. intravenous
(i.v.) CYC was discussed with the patient, and the risks and
benefits were explained. She chose treatment with i.v. CYC
and had started treatment with the NIH protocol with i.v.
CYC 750mg/m2 every month for four doses and prednisone
60mg daily, (tapered to 30mg daily).
Guideline 12.9: Treatment of resistant disease
12.9.1: In patients with worsening SCr and/or proteinuria
after completing one of the initial treatment
regimens, consider performing a repeat kidney
biopsy to distinguish active LN from scarring (not
graded).
12.9.2: Treat patients with worsening SCr and/or protei-
nuria who continue to have active LN on biopsy
with one of the alternative initial treatment regi-
mens (see Section 12.3) (not graded).
12.9.3: We suggest that nonresponders who have failed
more than one of the recommended initial regimens
(see Section 12.3) be considered for treatment with
rituximab, i.v. immunoglobulin, or CNIs (2D).
Four months after she had started treatment with the
NIH protocol with i.v. CYC at a dose of 750mg/m2
every month for four doses and prednisone at a dose
of 60mg daily (tapered to 30mg daily), her SCr level
had improved to 0.9mg/dl, proteinuria was persistent at
3.7 g/day, and the urine sediment showed 3–5 red blood
cells per high-power field. Lupus serologies showed per-
sistent elevation of anti-DNA antibodies, but complement
levels that were previously abnormal had normalized at this
time.
This patient has completed 4 months of therapy with CYC
and corticosteroids and, despite serological improvement and
improvement in renal function, has persistent nephrotic-
range proteinuria. Is this a resistant disease? On the basis of
the definitions of response (Table 1), the patient can be
considered a nonresponder (persistent nephrotic-range
proteinuria). What should be done at this point? Repeat a
kidney biopsy? Change treatment to an alternative regimen/
add therapy? Or continue the current therapy?
As discussed in the guideline, patients may take up to a
year to show response (only 50% of patients had a remission
(complete or partial) by 12 months, with another 5–25%
remitting by 24 months). Is a repeat kidney biopsy likely to
show therapeutically useful information? From a treatment
standpoint, in this patient with recent biopsy diagnosis of
Class IV LN, who is already on a standard induction regimen,
even if the biopsy were to show a change of lupus class (the
only possibility is a change to Class V LN), a repeat biopsy
would not likely be of benefit. The options now are to
continue the current therapy, or to switch to an alternate
regimen (e.g., MMF19) or to add on therapy (either a CNI20
or rituximab21). The observation that renal function is
improving as are serological parameters suggests that the
disease activity might be lessening and watchful waiting is
preferred. A renal biopsy might have been considered if renal
function was worsening while the patient was on induction
therapy (suggesting refractory disease, perhaps with progres-
sion of crescents).
The patient continued two more doses of CYC (total six
doses), and then was started on MMF maintenance therapy
1 g twice daily. After 12 months of MMF and prednisone dose
tapered down to 5mg/day, the urine protein decreased to
300mg/day, and the SCr level was 0.8mg/dl.
3. Membranous nephropathy
Guideline 7.1: Evaluation of membranous nephropathy (MN)
7.1.1: Perform appropriate investigations to exclude second-
ary causes in all cases of biopsy-proven MN (not
graded).
A 59-year-old obese patient presented with marked
swelling of his feet and a 2-week history of frothy urine. He
was not diabetic, but did have a family history of diabetes. A
biopsy showed MN with no significant interstitial or vascular
disease. On testing, he was found to have proteinuria of
Table 1 | Definitions of response to therapy in LN
Complete response: Return of SCr to previous baseline, plus a decline in
the uPCR to o500mg/g (o50mg/mmol).
Partial response: Stabilization (±25%) or improvement of SCr, but not to
normal, plus a 450% decrease in uPCR. If there was nephrotic-range
proteinuria (uPCR43000mg/g (4300mg/mmol)), improvement requires
a X450% reduction in uPCR and a uPCR of o3000mg/g (o300mg/
mmol).
Deterioration: There is no definition of deterioration in LN to define
treatment failure that has been tested prospectively as an indication to
change in initial therapy. A sustained 25% increase in SCr is widely used
but has not been validated.
Abbreviations: LN, lupus nephritis; SCr, serum creatinine; uPCR, urine protein
creatinine ratio.
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7 g/day, normal creatinine of 1.0 g/dl, and serum albumin of
2.9 g/l. All investigations for secondary causes (performed as
per guideline 7.1) are negative or normal. He was started on
conservative treatment including ACEi therapy, a low-
sodium diet, and diuretics. His symptoms improved, but
by the end of 3 months, his proteinuria had increased to 10 g/
day, albumin reduced to 2.6 g/day, and creatinine level was
1.3mg/dl.
7.2: Selection of adult patients with idiopathic MN (IMN)
to be considered for treatment with immuno-
suppressive agents
7.2.1: We recommend that initial therapy be started only in
patients with nephrotic syndrome and when at least
one of the following conditions is met:
K Urinary protein excretion persistently exceeds 4 g/day and
remains at over 50% of the baseline value,
and
K does not show progressive decline during antihyperten-
sive and antiproteinuric therapy during an observation
period of at least 6 months (1B);
or
K the presence of severe, disabling, or life-threatening
symptoms related to the nephrotic syndrome (1C);
or
K SCr level has risen by 30% or more within 6 to 12 months
from the time of diagnosis but the estimated glomerular
filtration rate (eGFR) is not less than 25–30ml/min per
1.73m2 and this change is not explained by superimposed
complications (2C).
Knowing who and when to treat remains one of the
most challenging issues in the management of the MN
patient.22 The original rule of thirds with regard to outcome
still applies:1/3 will have spontaneous remission, 1/3 will
have persistent proteinuria, and 1/3 will progress slowly to
renal failure. But how long to wait to see in which third
the patient fits remains a critical question.23,24 The reason
this is so important is that the risk of other complications of
the nephrotic syndrome, including loss of renal function
while waiting, must be weighed against early start of
immunosuppressive therapy and the risks that all of our
current options have in terms of adverse effects. Certainly,
it is clear with our current therapeutic options that the
risks exceed the benefits in the MN patient with non-
nephrotic-range proteinuria.25 This patient is heavily
nephrotic but has not reached the above standard of
6 months of conservative therapy. However, his albumin
level is decreasing, increasing the risk of thromboembolism,
and his creatinine is edging up, raising the question of
ongoing loss of functioning nephrons.26,27 In addition, he
is overweight and has a sedentary lifestyle, raising more
concerns with regard to the likelihood of a venous
thromboembolism. All of these characteristics argue for not
waiting until the end of 6 months before initiating
immunosuppressive therapy.
Guideline 7.3: Initial therapy of IMN
7.3.1: We recommend that initial therapy consist of a
6-month course of alternating monthly cycles of oral
and i.v. corticosteroids, and oral alkylating agents
(1B).
Guidline 7.4: Alternative regimens for the initial therapy of IMN
7.4.1: We recommend that cyclosporine or tacrolimus be
used for a period of at least 6 months in patients who
meet the criteria for initial therapy (as described in
Recommendation 7.2.1), but who choose not to
receive the cyclical corticosteroid/alkylating-agent
regimen or who have contraindications to this
regimen (1C).
In this case, there are additional features that warrant
considering the alternative to the strongest recommendation
of a 6-month course of alternating monthly cycles of oral and
i.v. corticosteroids and oral alkylating agents. Similar to the
patient with FSGS previously discussed, these features
include patient obesity and family history of diabetes. These
factors would significantly add to the risks of adverse events
associated with the high-dose boluses of solumedrol and the
total of 3 months of daily prednisone at a significant dose of
0.5mg/kg required with this regimen. These considerations
are relevant even knowing that the evidence in terms of a
lower relapse rate post treatment and the long-term results
favor this approach compared with CNI therapy28–31 (see
Sections 7.3.1 and 7.4.1).
Given the concerns about the risks of corticosteroids and
after discussion with the patient, the alternative initial
therapy using a CNI inhibitor was begun. Further helping
in this decision was the absence of interstitial/vascular
changes on biopsy and the well-preserved renal function,
because either significant fibrosis or marked renal impair-
ment can complicate the introduction and management of
CNI therapy.
7.4.3: We suggest that the dosage of CNIs be reduced at
intervals of 4–8 weeks to a level of about 50% of the
starting dosage, provided that remission is main-
tained and no treatment-limiting CNI-related ne-
phrotoxicity occurs, and continued for at least 12
months (2C).
7.4.4: We suggest that CNI blood levels be monitored
regularly during the initial treatment period, and
whenever there is an unexplained rise in SCr level
(420%) during therapy (not graded).
The patient responded to the CNI therapy, with
proteinuria decreasing slowly over 4 months to 2 g/day,
albumin rising to 3.4 g/dl, but the SCr level increasing from
1.3 to 2.0mg/dl with no obvious explanation.
The concern was that this rise in creatinine was related to
CNI nephrotoxicity. The first reaction to the marked change
was to stop the CNI abruptly. However, on careful review of
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the medications, it was noted the patient had been switched
inadvertently to a nondihydropyridine from a dihydro-
pyridine calcium channel blocker for his hypertension, and
his CNI level on repeat measurement had almost doubled.
Other potential factors such as volume depletion from diuretics
or intercurrent illness, and other drug-associated toxicities such
as interstitial nephritis, renal vein thrombosis, and drug
interactions, also need to be considered in this setting rather
than just assuming CNI nephrotoxicity. The latter is much less
likely in the glomerulonephritis (GN) setting compared with
the solid organ transplant field because of the lower starting
dose required in GN and the ability to slowly increase the
amount needed compared with the transplant situation.
With appropriate adjustment, the creatinine level returned
to baseline and the therapy was continued for 2 months at
3.5mg/kg/day. Thereafter, while watching the proteinuria
carefully, the dose was reduced as per the guideline before it
was discontinued at 12 months and after a complete
remission was achieved. The patient’s proteinuria remained
o0.3 g/day a year later off all immunosuppressive medica-
tions.
4. IgA nephropathy
Guideline 10.1: Initial evaluation including assessment of risk of
progressive kidney disease
10.1.1: Assess all patients with biopsy-proven IgA nephro-
pathy (IgAN) for secondary causes of IgAN (not
graded).
10.1.2: Assess the risk of progression in all cases by evalu-
ation of proteinuria, blood pressure (BP), and eGFR
at the time of diagnosis and during follow-up (not
graded).
10.1.3: Pathological features may be used to assess prog-
nosis (not graded).
Guideline 10.2: Antiproteinuric and antihypertensive therapy
10.2.1: We recommend long-term ACEi or angiotensin
receptor blockers (ARB) treatment when proteinuria
is41 g/day, with uptitration of the drug depending
on BP (1B).
10.2.2: We suggest ACEi or ARB treatment if proteinuria is
between 0.5 and 1 g/day (in children, between 0.5
and 1 g/day per 1.73m2) (2D).
10.2.3: We suggest that the ACEi or ARB be titrated upward as
far as tolerated to achieve proteinuria o1 g/day (2C).
10.2.4: In IgAN, use BP treatment goals of o130/80mmHg
in patients with proteinuria o1 g/day, and o125/
75mmHg when initial proteinuria is 41 g/day (not
graded).
A 28-year-old Caucasian male patient is discovered to
have microhematuria and proteinuria during his annual
physical examination. On further workup, his renal function
was found to be normal (creatinine 0.8mg/dl; eGFR4
60ml/min), and had proteinuria of 2.4 g/day . A renal biopsy
was performed, which showed IgAN; of 20 glomeruli,
5 glomerulis showed mesangial proliferation, 3 glomerulis
showed segmental endocapillary proliferation, and 1 glome-
ruli showed a circumferential crescent. Tubular atrophy
and interstitial fibrosis was seen in o10% of the biopsy
sample.
A critical part of the evaluation of patients with IgAN is to
predict risk for progession to renal failure. Traditionally,
clinical features such as persistent proteinuria 41 g/day,32
time-averaged proteinuria 41 g/day,33 uncontrolled hyper-
tension,34 and perhaps impaired GFR at presentation are
predictors of an adverse prognosis. In our patient, the degree
of proteinuria was in the ‘higher-risk’ range, but GFR was
normal. How do we incorporate biopsy findings into our
risk-assessment paradigm? The recent Oxford Classification
of IgAN has demonstrated the importance of (i) mesangial
hypercellularity, (ii) segmental glomerulosclerosis, (iii) endo-
capillary hypercellularity, and (iv) tubular atrophy/interstitial
fibrosis as independent variables predicting kidney outcome
on the kidney biopsy.35 In our patient, the ‘MEST score was
M0 (o50% mesangial hypercellularity), E1 (presence
of endocapillary proliferation), S0 (absence of segmental
glomerulosclerosis), and T0 (o25% tubule-interstitial fibro-
sis). This would translate to a GFR loss of approximately
3ml/year (compared with M0, E0, S0, and T0). Unfortu-
nately, there are yet no clinical trial data that have used
histological scoring systems to dictate therapy.
Thus, we are still essentially dependent on the degree of
proteinuria to determine prognosis. The threshold level of
proteinuria that heralds risk is uncertain. Most studies have
shown the threshold to be 1 g/day (especially time-averaged
values), but others have demonstrated that 0.5 g/day is the
threshold at which the risk begins to increase. Reduction of
proteinuria to o1 g/day is associated with a more favorable
prognosis irrespective of whether the initial proteinuria was
43 g or of lesser degrees. BP is also an important risk factor,
and if the proteinuria in patients is 41 g/day, a target
BPo125/75mmHg has been recommended. Although a
lower GFR at presentation is associated with end-stage renal
disease, it is not clear whether this factor is associated with a
faster rate of renal function decline. The use of ACEi or ARB
has been associated with proteinuria reduction and a
reduction in GFR decline in patients with proteinuria
41 g/day and, together with strict BP targets, should be
instituted in all IgAN patients who are at higher risk for
progression.36
The patient was started on a low dose of an ACEi, which
was gradually titrated up to a middle-range dose (further
uptitration was limited by symptomatic hypotension). After 3
months of therapy, the urine protein levels fluctuated
between 0.9 and 1.2 g/day. The SCr level was 0.9–1.0mg/dl.
Guideline 10.3: Corticosteroids
10.3.1: We suggest that patients with persistent proteinuria
41 g/day, despite 3–6 months of optimized supportive
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care (including ACEi or ARBs and BP control), and
GFR 450ml/min per 1.73m2 receive a 6-month
course of corticosteroid therapy (2C).
The use of corticosteroids in patients with persistent
proteinuria has been recommended by KDIGO guidelines,
but there are several caveats that the practitioner must be
aware of before embarking on this course. First, the studies
that have used corticosteroids with ACEi/ARB mandated the
withdrawal of the latter drugs for a month, and both drugs
were started after this period.37,38 Although the group treated
with steroids and ACEi did better than the group treated with
ACEi alone, it is possible that there might be low-risk patients
who might reduce proteinuria without corticosteroids (with
just the ACEi). Second, there are very little data on the use of
corticosteroids in patients with eGFRo50ml/min. Last, as
pointed out before, there are no data on the response rates
with respect to histological features.
The patient on ACEi was able to reduce proteinuria to
around 1 g/day, but not any further. Should we consider
therapy with corticosteroids at this point? A reexamination of
his risk factors is perhaps in order and the histology might
help us here. This patient’s biopsy showed endocapillary
proliferation, and although there were few crescents, it might
make us think that his disease is more aggressive and that he
might benefit from steroids (as opposed to a patient with
only mesangial proliferation).
After a detailed discussion, a course of corticosteroids was
recommended to the patient who agreed to the therapy. He
tolerated the medication without major side effects. After 3
months of therapy, his proteinuria decreased to 0.6 g/day, and
at the end of therapy at 6 months, he had 0.3 g/day of protein.
5. Pauci immune focal and segmental necrotizing GN
Guideline 13.1: Initial treatment
13.1.1: We recommend that CYC and corticosteroids be
used as initial treatment (1A).
13.1.2: We recommend that rituximab and corticosteroids
be used as an alternative initial treatment in patients
without severe disease or in whom CYC is contra-
indicated (1B).
Guideline 13.2: Special patient populations
13.2.1: We recommend the addition of plasmapheresis for
patients requiring dialysis or with rapidly increasing
SCr level (1C).
13.2.2: We suggest the addition of plasmapheresis for
patients with diffuse pulmonary hemorrhage (2C).
13.2.3: We suggest the addition of plasmapheresis for
patients with overlap syndrome of ANCA vasculitis
and anti-glioblastoma multiforme (GBM) GN,
according to proposed criteria and regimen for
anti-GBM GN (see Chapter 14) (2D).
13.2.4: We suggest discontinuing CYC therapy after 3
months in patients who remain dialysis dependent
and who do not have any extrarenal manifestations
of disease (2C).
Guideline 13.5: Treatment of relapse
13.5.1: We recommend treating patients with severe relapse
of ANCA vasculitis (life- or organ-threatening)
according to the same guidelines as for the initial
therapy (see Section 13.1) (1C).
A 78-year-old male patient presented with a remote
history of ANCAþ vasculitis 4 years ago. He responded to
treatment with CYC plus corticosteroids (see Section 13.1.1),
which was followed by 18 months of treatment with
azathioprine at 1–1.5mg/kg/day. He had a complete remis-
sion of his disease, but his ANCA remained positive. For the
past 12 months he has been off all immunosuppression and
has remained stable. Some problems remained that were
presumed to be partly related to the CYC/azathioprine
therapy, i.e., a mild leucopenia, 3.1–3.6, with an absolute
neutrophil count of B 1500. He also developed type 2
diabetes mellitus during his treatment of the vasculitis, but
this was well controlled with metformin therapy.
He presented with a 1-week history of shortness of breath,
a nasal discharge, and increasing fatigue plus minor swelling
of the ankles. Physical examination revealed some nasal
crusting, fine basal crepitations in the chest bilaterally, and on
laboratory testing, he had an active urine sediment and a
creatinine level that had increased from 1mg/dl at his last
routine visit 3 months ago to 2mg/dl, 3þ urine protein on
dipstick exam, anemia with a hemoglobin of 11 g/l, and mild
hypoxemia (92% fiO2). His peripheral ANCA test remained
positive.
Although the guideline recommendation is to repeat the
initial course (see Section 13.5.1), i.e., CYC and corticosteroids
given their success in inducing a remission in the past but the
persistent leucopenia was a concern in terms of infectious risk
with another full course of CYC. In addition, the low white cell
count may limit the total dosage that can be given, leaving the
possibility of inadequate CYC exposure, resulting in a failure
to induce a second remission. At this point, a change to a
rituximab-based treatment regimen was seriously considered
given its lack of bone marrow toxicity and after a review of the
RAVE trial data39 that indicated that rituximab has at least an
equal if not better chance of inducing a remission in relapsing
vasculitis than CYC.
Rituximab treatment was initiated along with a standard
corticosteroid induction routine, and within days, the patient
felt better and the SCr level stabilized.
Guideline 13.2: Special patient populations
13.2.1: We recommend the addition of plasmapheresis for
patients requiring dialysis or with rapidly increasing
SCr level (1C).
13.2.2: We suggest the addition of plasmapheresis for
patients with diffuse pulmonary hemorrhage (2C).
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13.2.3: We suggest the addition of plasmapheresis for
patients with overlap syndrome of ANCA vasculitis
and anti-GBM GN, according to proposed criteria
and regimen for anti-GBM GN (2D).
13.2.4: We suggest discontinuing CYC therapy after 3
months in patients who remain dialysis dependent
and who do not have any extrarenal manifestations
of disease (2C).
However, the patient’s oxygen saturation deteriorated
and he had several episodes of hemoptysis. A chest X-ray
indicated increasing pulmonary infiltrates. Appropriate
cultures were taken and broad-spectrum antibiotics were
initiated to cover the possibility of infection, but the worry
was that this was part of his vasculitis relapse. Plasmapheresis
was begun following the below routine.
Plasmapheresis: 60ml/kg volume replacement.
Vasculitis: Seven treatments over 14 days if diffuse pulmo-
nary hemorrhage, daily until the bleeding stops, then every
other day, total of 7–10 treatments.
Although no prospective studies have been conducted
with regard to plasmapheresis under these circumstances,
retrospective studies have indicated that it can improve the
pulmonary findings.40,41 More importantly, from a clinical
perspective, the impact of such treatment is high, i.e.,
reduction in mortality42,43 and risk is quite low.
Guideline 13.3: Maintenance therapy
13.3.1: We recommend maintenance therapy in patients
who have achieved remission (1B).
13.3.2: We suggest continuing maintenance therapy for at
least 18 months in patients who remain in complete
remission (2D).
13.3.3: We recommend no maintenance therapy in patients
who are dialysis dependent and have no extrarenal
manifestations of disease (1C).
Guideline 13.4: Choice of agent for maintenance therapy
13.4.1: We recommend azathioprine 1–2mg/kg/day orally
as maintenance therapy (1B).
13.4.2: We suggest that MMF, up to a dose of 1 g twice daily,
be used for maintenance therapy in patients who are
allergic to, or intolerant of, azathioprine (2C).
13.4.3: We suggest trimethoprim-sulfamethoxazole as an
adjunct to maintenance therapy in patients with
upper respiratory tract disease (2B).
13.4.4: We suggest methotrexate (initially 0.3mg/kg/week,
maximum 25mg/week) for maintenance therapy in
patients intolerant of azathioprine and MMF, but
not if GFR is o60ml/min per 1.73m2 (1C).
13.4.5: We recommend not using etanercept as adjunctive
therapy (1A).
Initially, there was no response, but by the end of the third
plasma exchange the hemorrhage stopped, the patient
recovered normal pulmonary function, and his creatinine
and proteinuria improved over the next 2 months. However,
his diabetes worsened and he became insulin dependent.
Given the previous leucopenia, we opted to introduce MMF
at a 1-gm b.i.d. and added trimethoprim-sulfamethoxazole
given that this relapse had been associated with upper airway
disease.
How long the maintenance therapy should be continued
has not been answered. In this case, given the relapse and its
severity, plus the patient’s age, and now his worsened
comorbid condition (i.e., insulin dependent diabetes), we slowly
reduced the MMF to 500mg b.i.d. and tapered his steroids to
only 5mg/day. He has remained very stable over the last year
and after considering the risk/benefits, we have decided to
maintain this lower degree of immunosuppression indefinitely.
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APPENDIX
Summary of Recommendation Statements
Chapter 3: SSNS in children
3.1: Treatment of the initial episode of SSNS
3.1.1: We recommend that corticosteroid therapy (prednisone or prednisolone; prednisone and prednisolone are equivalent,
are used in the same dosage, and have both been used in randomized controlled trials depending on the country of
origin; all later references to prednisone in this chapter refer to prednisone or prednisolone; all later references to oral
corticosteroids refer to prednisone or prednisolone) be given for at least 12 weeks. (1B)
3.1.1.1: We recommend that oral prednisone be administered as a single daily dose (1B) starting at 60 or 2mg/kg/day to a
maximum dose of 60mg/day. (1D)
3.1.1.2: We recommend that daily oral prednisone be given for 4–6 weeks (1C) followed by alternate-day medication as a
single daily dose starting at 40mg/m2 or 1.5mg/kg (a maximum dose of 40mg on alternate days) (1D) and continued
for 2–5 months with tapering of the dose. (1B)
3.2: Treatment of relapsing SSNS with corticosteroids
3.2.1: Corticosteroid therapy for children with infrequent relapses of steroid-sensitive nephrotic syndrome (SSNS):
3.2.1.1: We suggest that infrequent relapses of SSNS in children be treated with a single daily dose of prednisone 60mg/m2 or
2mg/kg (maximum of 60mg/day) until the child has been in complete remission for at least 3 days. (2D)
3.2.1.2: We suggest that, after achieving complete remission, children be given prednisone as a single dose on alternate days
(40 or 1.5mg/kg/dose: a maximum dose of 40mg on alternate days) for at least 4 weeks. (2C)
3.2.2: Corticosteroid therapy for frequently relapsing (FR) and steroid-dependent (SD) SSNS:
3.2.2.1: We suggest that relapses in children with FR or SD SSNS be treated with daily prednisone until the child has been in
remission for at least 3 days, followed by alternate-day prednisone for at least 3 months. (2C)
3.2.2.2: We suggest that prednisone be given on alternate days in the lowest dose to maintain remission without major
adverse effects in children with FR and SD SSNS. (2D)
3.2.2.3: We suggest that daily prednisone at the lowest dose be given to maintain remission without major adverse effects in
children with SD SSNS in whom alternate-day prednisone therapy is not effective. (2D)
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3.2.2.4: We suggest that daily prednisone be given during episodes of upper respiratory tract and other infections to reduce
the risk for relapse in children with FR and SD SSNS already on alternate-day prednisone. (2C)
3.3: Treatment of FR and SD SSNS with corticosteroid-sparing agents
3.3.1: We recommend that corticosteroid-sparing agents be prescribed for children with FR SSNS and SD SSNS, who
develop steroid-related adverse effects. (1B)
3.3.2: We recommend that alkylating agents, CYC, or chlorambucil be given as corticosteroid-sparing agents for FR SSNS. (1B)
We suggest that alkylating agents, CYC, or chlorambucil be given as corticosteroid-sparing agents for SD SSNS. (2C)
3.3.2.1: We suggest that CYC (2mg/kg/day) be given for 8–12 weeks (maximum cumulative dose 168mg/kg). (2C)
3.3.2.2: We suggest that CYC not be started until the child has achieved remission with corticosteroids. (2D)
3.3.2.3: We suggest that chlorambucil (0.1–0.2mg/kg/day) be given for 8 weeks (maximum cumulative dose 11.2mg/kg) as an
alternative to CYC. (2C)
3.3.2.4: We suggest that second courses of alkylating agents not be given. (2D)
3.3.3: We recommend that levamisole be given as a corticosteroid-sparing agent. (1B)
3.3.3.1: We suggest that levamisole be given at a dose of 2.5mg/kg on alternate days (2B) for at least 12 months (2C), as most
children will undergo relapse when levamisole is stopped.
3.3.4: We recommend that the CNIs cyclosporine or tacrolimus be given as corticosteroid-sparing agents. (1C)
3.3.4.1: We suggest that cyclosporine be administered at a dose of 4–5mg/kg/day (starting dose) in two divided doses. (2C)
3.3.4.2: We suggest that tacrolimus 0.1mg/kg/day (starting dose) given in two divided doses be used instead of cyclosporine when
the cosmetic side effects of cyclosporine are unacceptable. (2D)
3.3.4.3: Monitor CNI levels during therapy to limit toxicity (Not Graded).
3.3.4.4: We suggest that CNIs be given for at least 12 months, as most children will undergo relapse when CNIs are stopped. (2C)
3.3.5: We suggest that MMF be given as a corticosteroid-sparing agent. (2C)
3.3.5.1: We suggest that MMF (starting dose 1200mg/m2/day) be given in two divided doses for at least 12 months, as most
children will undergo relapse when MMF is stopped. (2C)
3.3.6: We suggest that rituximab be considered only in children with SD SSNS, who have continuing FRs despite optimal
combinations of prednisone and corticosteroid-sparing agents, and/or who have serious adverse effects of therapy. (2C)
3.3.7: We suggest that mizoribine not be used as a corticosteroid-sparing agent in FR and SD SSNS. (2C)
3.3.8: We recommend that azathioprine not be used as a corticosteroid-sparing agent in FR and SD SSNS. (1B)
3.4: Indication for kidney biopsy
3.4.1: Indications for kidney biopsy in children with SSNS are as follows (Not Graded):
K late failure to respond following initial response to corticosteroids;
K a high index of suspicion for a different underlying pathology;
K decreasing kidney function in children receiving CNIs.
3.5: Immunizations in children with SSNS
3.5.1: To reduce the risk of serious infections in children with SSNS (Not Graded), the following steps should be taken:
K Give pneumococcal vaccination to the children.
K Give influenza vaccination annually to the children and their household contacts.
K Defer vaccination with live vaccines until prednisone dose is below either 1mg/kg daily (o20mg/day) or 2mg/kg
on alternate days (o40mg on alternate days).
K Live vaccines are contraindicated in children receiving corticosteroid-sparing immunosuppressive agents.
K Immunize healthy household contacts with live vaccines to minimize the risk of transfer of infection to the
immunosuppressed child, but avoid direct exposure of the child to gastrointestinal, urinary, or respiratory
secretions of vaccinated contacts for 3–6 weeks after vaccination.
K Following close contact with Varicella infection, give nonimmune children on immunosuppressive agents varicella
zoster immune globulin, if available.
Chapter 4: SRNS in children
4.1: Evaluation of children with SRNS
4.1.1: We suggest a minimum of 8 weeks of treatment with corticosteroids to define steroid resistance. (2D)
4.1.2: The following are required to evaluate the child with steroid-resistant nephrotic syndrome (SRNS; not graded):
K a diagnostic kidney biopsy;
K evaluation of kidney function by GFR or eGFR;
K quantification of urine protein excretion.
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4.2: Treatment recommendations for SRNS
4.2.1: We recommend using a CNI as initial therapy for children with SRNS. (1B)
4.2.1.1: We suggest that CNI therapy be continued for a minimum of 6 months and then stopped if a partial or complete
remission of proteinuria is not achieved. (2C)
4.2.1.2: We suggest that CNIs be continued for a minimum of 12 months when at least a partial remission is achieved by
6 months. (2C)
4.2.1.3: We suggest that low-dose corticosteroid therapy be combined with CNI therapy. (2D)
4.2.2: We recommend treatment with ACEi or ARBs for children with SRNS. (1B)
4.2.3: In children who fail to achieve remission with CNI therapy:
4.2.3.1: We suggest that MMF (2D), high-dose corticosteroids (2D), or a combination of these agents (2D) be considered in
children who fail to achieve complete or partial remission with CNIs and corticosteroids.
4.2.3.2: We suggest that CYC not be given to children with SRNS. (2B)
4.2.4: In patients with a relapse of nephrotic syndrome after complete remission, we suggest that therapy be restarted using
any one of the following options (2C):
K oral corticosteroids (2D);
K return to previous successful immunosuppressive agent (2D);
K an alternative immunosuppressive agent to minimize potential cumulative toxicity. (2D)
Chapter 5: MCD in adults
5.1: Treatment of initial episode of adult MCD
5.1.1: We recommend that corticosteroids be given for initial treatment of nephrotic syndrome (1C).
5.1.2: We suggest that prednisone or prednisolone (prednisone and prednisolone are equivalent, used in the same dosage,
and have both been used in randomized controlled trials depending on the country of origin; all later references to
prednisone in this chapter refer to prednisone or prednisolone; all later references to oral corticosteroids refer to
prednisone or prednisolone) be given at a daily single dose of 1mg/kg (maximum 80mg) or at an alternate-day single
dose of 2mg/kg (a maximum dose of 120mg). (2C)
5.1.3: We suggest that the initial high dose of corticosteroids, if tolerated, be maintained for a minimum period of 4 weeks if
complete remission is achieved, and for a maximum period of 16 weeks if complete remission is not achieved. (2C)
5.1.4: In patients who remit, we suggest that corticosteroids be tapered slowly over a total period of up to 6 months after
achieving remission. (2D)
5.1.5: For patients with relative contraindications or intolerance to high-dose corticosteroids (e.g., uncontrolled diabetes,
psychiatric conditions, severe osteoporosis), we suggest treatment with oral CYC or CNIs as discussed in FR minimal-
change disease (MCD). (2D)
5.1.6: We suggest using the same initial dose and duration of corticosteroids for infrequent relapses as in Recommendations
5.1.2, 5.1.3, and 5.1.4. (2D)
5.2: FR/SD minimal-change disease
5.2.1: We suggest using oral CYC at a dose of 2–2.5mg/kg/day for 8 weeks. (2C)
5.2.2: We suggest CNI (cyclosporine 3–5mg/kg/day or tacrolimus 0.05–0.1mg/kg/day in divided doses) for 1–2 years for
FR/SD MCD patients who have relapsed despite CYC, or for people who wish to preserve their fertility. (2C)
5.2.3: We suggest the use of MMF 500–1000mg twice daily for 1–2 years for patients who are intolerant of corticosteroids,
CYC, and CNIs. (2D)
5.3: Corticosteroid-resistant MCD
5.3.1: Reevaluate patients who are corticosteroid-resistant for other causes of nephrotic syndrome (Not Graded).
5.4: Supportive therapy
5.4.1: We suggest that MCD patients who have acute kidney injury (AKI) be treated with renal replacement therapy as
indicated, but together with corticosteroids, as for a first episode of MCD. (2D)
5.4.2: We suggest that, for the initial episode of nephrotic syndrome associated with MCD, statins not be used to treat
hyperlipidemia, and ACEi or ARBs not be used in normotensive patients to lower proteinuria. (2D)
Chapter 6: Idiopathic FSGS in adults
6.1: Initial evaluation of FSGS
6.1.1: Undertake thorough evaluation to exclude secondary forms of FSGS (Not Graded).
6.1.2: Do not routinely perform genetic testing (Not Graded).
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6.2: Initial treatment of FSGS
6.2.1: We recommend that corticosteroid and immunosuppressive therapy be considered only in idiopathic FSGS associated
with clinical features of the nephrotic syndrome. (1C)
6.2.2: We suggest prednisone (prednisone and prednisolone are equivalent, used in the same dosage, and have both
been used in randomized controlled trials depending on the country of origin; all later references to prednisone in this
chapter refer to prednisone or prednisolone; all later references to oral corticosteroids refer to prednisone or
prednisolone) be given at a daily single dose of 1mg/kg (a maximum dose of 80mg) or at an alternate-day dose of
2mg/kg (maximum 120mg). (2C)
6.2.3: We suggest the initial high dose of corticosteroids be given for a minimum of 4 weeks; continue high-dose
corticosteroids up to a maximum of 16 weeks, as tolerated, or until complete remission has been achieved, whichever
is earlier. (2D)
6.2.4: We suggest corticosteroids be tapered slowly over a period of 6 months after achieving complete remission. (2D)
6.2.5: We suggest CNIs be considered as first-line therapy for patients with relative contraindications or intolerance to high-
dose corticosteroids (e.g., uncontrolled diabetes, psychiatric conditions, severe osteoporosis). (2D)
6.3: Treatment for relapse
6.3.1: We suggest that a relapse of nephrotic syndrome be treated as per the recommendations for relapsing MCD in adults
(see Chapters 5.1 and 5.2). (2D)
6.4: Treatment for steroid-resistant FSGS
6.4.1: For steroid-resistant FSGS, we suggest that cyclosporine at 3–5mg/kg/day in divided doses be given for at least 4–6
months. (2B)
6.4.2: If there is a partial or complete remission, we suggest continuing cyclosporine treatment for at least 12 months,
followed by a slow taper. (2D)
6.4.3: We suggest that patients with steroid-resistant FSGS, who do not tolerate cyclosporine, be treated with a combination
of MMF and high-dose dexamethasone. (2C)
Chapter 7: Idiopathic MN
7.1: Evaluation of MN
7.1.1: Perform appropriate investigations to exclude secondary causes in all cases of biopsy-proven MN (Not Graded).
7.2: Selection of adult patients with IMN to be considered for treatment with immunosuppressive agents (see Section 7.8 for
recommendations for children with IMN).
7.2.1: We recommend that initial therapy be started only in patients with nephrotic syndrome and when at least one of the
following conditions is met:
K Urinary protein excretion persistently exceeds 4 g/day and remains at over 50% of the baseline value, and does not
show progressive decline during antihypertensive and antiproteinuric therapy (see Chapter 1), during an
observation period of at least 6 months (1B);
K the presence of severe, disabling, or life-threatening symptoms related to the nephrotic syndrome (1C);
K SCr level has risen by 30% or more within 6 to 12 months from the time of diagnosis, but the eGFR is not less than
25–30ml/min per 1.73m2 and this change is not explained by superimposed complications. (2C)
7.2.2: Do not use immunosuppressive therapy in patients with an SCr level persistently43.5mg/dl (4309 mmol/l; or an eGFR
o30ml/min per 1.73m2) and reduction of kidney size on ultrasound (e.g.,o8 cm in length) or those with concomitant
severe or potentially life-threatening infections (Not Graded).
7.3: Initial therapy of IMN
7.3.1: We recommend that initial therapy consist of a 6-month course of alternating monthly cycles of oral and i.v.
corticosteroids and oral alkylating agents (see Table 15). (1B)
7.3.2: We suggest using CYC rather than chlorambucil for initial therapy. (2B)
7.3.3: We recommend that patients be managed conservatively for at least 6 months following the completion of this
regimen before being considered a treatment failure if there is no remission, unless kidney function is deteriorating or
severe, disabling, or potentially life-threatening symptoms related to the nephrotic syndrome are present (see also
Recommendation 7.2.1). (1C)
7.3.4: Perform a repeat kidney biopsy only if the patient has rapidly deteriorating kidney function (doubling of SCr level
over 1–2 month of observation), in the absence of massive proteinuria (415 g/day) (Not Graded).
7.3.5: Adjust the dose of CYC or chlorambucil according to the age of the patient and eGFR (Not Graded).
7.3.6: We suggest that continuous daily (noncyclic) use of oral alkylating agents may also be effective, but can be associated
with greater risk of toxicity, particularly when administered for 46 months. (2C)
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7.4: Alternative regimens for the initial therapy of IMN: CNI therapy
7.4.1: We recommend that cyclosporine or tacrolimus be used for a period of at least 6 months in patients who meet the
criteria for initial therapy (as described in Recommendation 7.2.1), but who choose not to receive the cyclical
corticosteroid/alkylating-agent regimen, or who have contraindications to this regimen (see Table 18 for specific
recommendations for dosage during therapy). (1C)
7.4.2: We suggest that CNIs be discontinued in patients who do not achieve complete or partial remission after 6 months of
treatment. (2C)
7.4.3: We suggest that the dosage of CNI be reduced at intervals of 4–8 weeks to a level of about 50% of the starting dosage,
provided that remission is maintained and no treatment-limiting CNI-related nephrotoxicity occurs, and continued
for at least 12 months. (2C)
7.4.4: We suggest that CNI blood levels be monitored regularly during the initial treatment period, and whenever there is an
unexplained rise in SCr level (420%) during therapy (not graded; see Table 18 for specific CNI-based regimen dosage
recommendations).
7.5: Regimens not recommended or suggested for initial therapy of IMN
7.5.1: We recommend that corticosteroid monotherapy not be used for initial therapy of IMN (1B).
7.5.2: We suggest that monotherapy with MMF not be used for initial therapy of IMN. (2C)
7.6: Treatment of IMN resistant to recommended initial therapy
7.6.1: We suggest that patients with IMN resistant to alkylating agent/steroid-based initial therapy be treated with a CNI.
(2C)
7.6.2: We suggest that patients with IMN resistant to CNI-based initial therapy be treated with an alkylating agent/steroid-
based therapy. (2C)
7.7: Treatment for relapses of nephrotic syndrome in adults with IMN
7.7.1: We suggest that relapses of nephrotic syndrome in IMN be treated by reinstitution of the same therapy that resulted in
the initial remission. (2D)
7.7.2: We suggest that, if a 6-month cyclical corticosteroid/alkylating-agent regimen was used for initial therapy (see
Recommendation 7.3.1), the regimen be repeated only once for treatment of a relapse. (2B)
7.8: Treatment of IMN in children
7.8.1: We suggest that treatment of IMN in children follows the recommendations for treatment of IMN in adults (2C; see
Recommendations 7.2.1 and 7.3.1).
7.8.2: We suggest that no more than one course of the cyclical corticosteroid/alkylating-agent regimen be given in children. (2D)
7.9: Prophylactic anticoagulants in IMN
7.9.1: We suggest that patients with IMN and nephrotic syndrome, with marked reduction in serum albumin (o2.5 g/dl
(o25 g/l)) and additional risks for thrombosis, be considered for prophylactic anticoagulant therapy, using oral
warfarin. (2C)
Chapter 8: Idiopathic MPGN
8.1: Evaluation of MPGN
8.1.1: Evaluate patients with the histological (light-microscopic) pattern of membranoproliferative GN (MPGN) for
underlying diseases before considering a specific treatment regimen (see Table 20; not graded).
8.2: Treatment of idiopathic MPGN
8.2.1: We suggest that adults or children with presumed idiopathic MPGN accompanied by nephrotic syndrome, and
progressive decline of kidney function receive oral CYC or MMF plus low-dose alternate-day or daily corticosteroids
with initial therapy limited to less than 6 months. (2D)
Chapter 9: Infection-related GN
9.1: For the following infection-related GN, we suggest appropriate treatment of the infectious disease and standard
approaches to management of the kidney manifestations (2D):
K poststreptococcal GN;
K infective endocarditis-related GN;
K shunt nephritis.
9.2: Hepatitis C virus (HCV) infection–related GN
Please also refer to the published KDIGO CPGs for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in
Chronic Kidney Disease.
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9.2.1: For HCV-infected patients with CKD stages 1 or 2 and GN, we suggest combined antiviral treatment using pegylated
interferon and ribavirin as in the general population (2C; based on KDIGO HCV Recommendation 2.2.1).
9.2.1.1: Titrate ribavirin dose according to patient tolerance and level of renal function (Not Graded).
9.2.2: For HCV-infected patients with CKD stages 3, 4, or 5 and GN not yet on dialysis, we suggest monotherapy with
pegylated interferon, with doses adjusted to the level of kidney function (2D; based on KDIGO HCV
Recommendation 2.2.2).
9.2.3: For patients with HCV and mixed cryoglobulinemia (IgG/IgM) with nephrotic proteinuria or evidence of progressive
kidney disease, or an acute flare of cryoglobulinemia, we suggest plasmapheresis, rituximab, or CYC, in conjunction
with i.v. methylprednisolone, and concomitant antiviral therapy. (2D)
9.3: Hepatitis B virus (HBV) infection–related GN
9.3.1: We recommend that patients with HBV infection and GN receive treatment with interferon-a or with nucleoside
analogs as recommended for the general population by standard CPGs for HBV infection (see Table 23; 1C).
9.3.2: We recommend that the dosing of these antiviral agents be adjusted to the degree of kidney function. (1C)
9.4: HIV infection–related glomerular disorders
9.4.1: We recommend that antiretroviral therapy be initiated in all patients with biopsy-proven HIV-associated nephropathy,
regardless of CD4 count. (1B)
9.5: Schistosomal, filarial, and malarial nephropathies
9.5.1: We suggest that patients with GN and concomitant malarial, schistosomal, or filarial infection be treated with an
appropriate antiparasitic agent in sufficient dosage and duration to eradicate the organism (Not Graded).
9.5.2: We suggest that corticosteroids or immunosuppressive agents not be used for treatment of schistosomal-associated GN,
as the GN is believed to be the direct result of infection and the attendant immune response to the organism. (2D)
9.5.3: We suggest that blood culture for Salmonella be considered in all patients with hepatosplenic schistosomiasis, who show
urinary abnormalities and/or reduced GFR. (2C)
9.5.3.1: We suggest that all patients who show a positive blood culture for Salmonella receive anti-Salmonella therapy. (2C)
Chapter 10: IgA nephropathy
10.1: Initial evaluation including assessment of risk of progressive kidney disease
10.1.1: Assess all patients with biopsy-proven IgAN for secondary causes of IgAN (Not Graded).
10.1.2: Assess the risk of progression in all cases by evaluation of proteinuria, BP, and eGFR at the time of diagnosis and
during follow-up (Not Graded).
10.1.3: Pathological features may be used to assess prognosis (Not Graded).
10.2: Antiproteinuric and antihypertensive therapy
10.2.1: We recommend long-term ACEi or ARB treatment when proteinuria is 41 g/day, with uptitration of the drug
depending on BP. (1B)
10.2.2: We suggest ACEi or ARB treatment if proteinuria is between 0.5 and 1 g/day (in children, between 0.5 and 1 g/day per
1.73m2). (2D)
10.2.3: We suggest the ACEi or ARB be titrated upward as far as tolerated, to achieve proteinuria o1 g/day. (2C)
10.2.4: In IgAN, use BP treatment goals of o130/80mmHg in patients with proteinuria o1 g/day, and o125/75mmHg
when initial proteinuria is 41 g/day (see Chapter 2) (Not Graded).
10.3: Corticosteroids
10.3.1: We suggest that patients with persistent proteinuria X1 g/day, despite 3–6 months of optimized supportive care
(including ACEi or ARBs and BP control), and GFR 450ml/min per 1.73m2 receive a 6-month course of
corticosteroid therapy. (2C)
10.4: Immunosuppressive agents (CYC, azathioprine, MMF, cyclosporine)
10.4.1: We suggest not treating with corticosteroids combined with CYC or azathioprine in IgAN patients (unless there is
crescentic IgAN with rapidly deteriorating kidney function; see Recommendation 10.6.3). (2D)
10.4.2: We suggest not using immunosuppressive therapy in patients with GFR o30ml/min per 1.73m2 unless there is
crescentic IgAN with rapidly deteriorating kidney function; see Section 10.6. (2C)
10.4.3: We suggest not using MMF in IgAN. (2C)
10.5: Other treatments
10.5.1: Fish oil treatment
10.5.1.1: We suggest using fish oil in the treatment of IgAN with persistent proteinuria X1 g/day, despite 3–6 months of
optimized supportive care (including ACEi or ARBs and BP control). (2D)
10.5.2: Antiplatelet agents
10.5.2.1: We suggest not using antiplatelet agents to treat IgAN. (2C)
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10.5.3: Tonsillectomy
10.5.3.1: We suggest that tonsillectomy not be performed for IgAN. (2C)
10.6: Atypical forms of IgAN
10.6.1: MCD with mesangial IgA deposits
10.6.1.1: We recommend treatment as for MCD (see Chapter 5) in nephrotic patients showing pathological findings of MCD
with mesangial IgA deposits on kidney biopsy. (2B)
10.6.2: AKI associated with macroscopic hematuria
10.6.2.1: Perform a repeat kidney biopsy in IgAN patients with AKI associated with macroscopic hematuria if, after 5 days
from the onset of kidney function worsening, there is no improvement (Not Graded).
10.6.2.2: We suggest general supportive care for AKI in IgAN, with a kidney biopsy performed during an episode of
macroscopic hematuria showing only acute tubular necrosis and intratubular erythrocyte casts. (2C)
10.6.3: Crescentic IgAN
10.6.3.1: Define crescentic IgAN as IgAN with crescents in more than 50% of glomeruli in the renal biopsy with rapidly
progressive renal deterioration (Not Graded).
10.6.3.2: We suggest the use of steroids and CYC in patients with IgAN and rapidly progressive crescentic IgAN, analogous to
the treatment of ANCA vasculitis (see Chapter 13). (2D)
Chapter 11: Henoch–Scho¨nlein purpura nephritis
11.1: Treatment of HSP nephritis in children
11.1.1: We suggest that children with Henoch–Scho¨nlein purpura (HSP) nephritis and persistent proteinuria, 40.5–1 g/day
per 1.73m2, are treated with ACEi or ARBs. (2D)
11.1.2: We suggest that children with persistent proteinuria, 41 g/day per 1.73m2, after a trial of ACEi or ARBs, and GFR
450ml/min per 1.73m2, be treated the same as for IgAN with a 6-month course of corticosteroid therapy
(see Chapter 10). (2D)
11.2: Treatment of crescentic HSP nephritis in children
11.2.1: We suggest that children with crescentic HSP with nephrotic syndrome and/or deteriorating kidney function be
treated in the same way as for crescentic IgAN; see Recommendation 10.6.3. (2D)
11.3: Prevention of HSP nephritis in children
11.3.1: We recommend not using corticosteroids to prevent HSP nephritis (1B).
11.4: HSP nephritis in adults
11.4.1: We suggest that HSP nephritis in adults be treated the same as in children. (2D)
Chapter 12: Lupus nephritis
12.1: Class I LN (minimal-mesangial LN)
12.1.1: We suggest that patients with class I LN be treated as dictated by the extrarenal clinical manifestations of lupus. (2D)
12.1: Class I LN (minimal–mesangial LN)
12.1.1: We suggest that patients with class I LN be treated as dictated by the extrarenal clinical manifestations of lupus. (2D)
12.2: Class II LN (mesangial proliferative LN)
12.2.1: Treat patients with class II LN and proteinuriao1 g/day as dictated by the extrarenal clinical manifestations of lupus.
(2D)
12.2.2: We suggest that class II LN with proteinuria43 g/day be treated with corticosteroids or CNIs as described for MCD
(see Chapter 5; 2D).
12.3: Class III LN (focal LN) and class IV LN (diffuse LN)—initial therapy
12.3.1: We recommend initial therapy with corticosteroids (1A), combined with either CYC (1B) or MMF (1B).
12.3.2: We suggest that, if patients have worsening LN (rising SCr level, worsening proteinuria) during the first 3 months of
treatment, a change be made to an alternative recommended initial therapy, or a repeat kidney biopsy be performed to
guide further treatment. (2D)
12.4: Class III LN (focal LN) and class IV LN (diffuse LN)—maintenance therapy
12.4.1: We recommend that, after initial therapy is complete, patients with class III and IV LN receive maintenance therapy
with azathioprine (1.5–2.5mg/kg/day) or MMF (1–2 g/day in divided doses) and low-dose oral corticosteroids
(p10mg/day prednisone equivalent) (1B).
12.4.2: We suggest that CNIs with low-dose corticosteroids be used for maintenance therapy in patients who are intolerant of
MMF and azathioprine. (2C)
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12.4.3: We suggest that, after complete remission is achieved, maintenance therapy be continued for at least 1 year before
consideration is given to tapering the immunosuppression. (2D)
12.4.4: If complete remission has not been achieved after 12 months of maintenance therapy, consider performing a repeat
kidney biopsy before determining if a change in therapy is indicated (Not Graded).
12.4.5: While maintenance therapy is being tapered, if kidney function deteriorates and/or proteinuria worsens, we suggest
that treatment be increased to the previous level of immunosuppression that controlled the LN. (2D)
12.5: Class V LN (membranous LN)
12.5.1: We recommend that patients with class V LN, normal kidney function, and nonnephrotic-range proteinuria be treated
with antiproteinuric and antihypertensive medications, and only receive corticosteroids and immunosuppressives as
dictated by the extrarenal manifestations of systemic lupus. (2D)
12.5.2: We suggest that patients with pure class V LN and persistent nephrotic proteinuria be treated with corticosteroids plus
an additional immunosuppressive agent: CYC (2C), or CNI (2C), or MMF (2D), or azathioprine. (2D)
12.6: General treatment of LN
12.6.1: We suggest that all patients with LN of any class be treated with hydroxychloroquine (maximum daily dose of
6–6.5mg/kg ideal body weight), unless they have a specific contraindication to this drug. (2C)
12.7: Class VI LN (advanced sclerosis LN)
12.7.1: We recommend that patients with class VI LN be treated with corticosteroids and immunosuppressives only as
dictated by the extrarenal manifestations of systemic lupus. (2D)
12.8: Relapse of LN
12.8.1: We suggest that a relapse of LN after complete or partial remission be treated with the initial therapy followed by the
maintenance therapy that was effective in inducing the original remission. (2B)
12.8.1.1: If resuming the original therapy would put the patient at risk for excessive lifetime CYC exposure, then we suggest a
non-CYC-based initial regimen be used (Regimen D, Table 28). (2B)
12.8.2: Consider a repeat kidney biopsy during relapse if there is suspicion that the histological class of LN has changed, or
if there is uncertainty whether a rising SCr level and/or worsening proteinuria represents disease activity or
chronicity (Not Graded).
12.9: Treatment of resistant disease
12.9.1: In patients with worsening SCr level and/or proteinuria after completing one of the initial treatment regimens,
consider performing a repeat kidney biopsy to distinguish active LN from scarring (Not Graded).
12.9.2: Treat patients with worsening SCr level and/or proteinuria who continue to have active LN on biopsy with one of the
alternative initial treatment regimens; see Section 12.3 (Not Graded).
12.9.3: We suggest that nonresponders who have failed more than one of the recommended initial regimens (see Section 12.3)
be considered for treatment with rituximab, i.v. Ig, or CNIs. (2D)
12.10: Systemic lupus and thrombotic microangiopathy
12.10.1: We suggest that the antiphospholipid antibody syndrome involving the kidney in systemic lupus patients, with or
without LN, be treated by anticoagulation (target international normalized ratio 2–3). (2D)
12.10.2: We suggest that patients with systemic lupus and thrombotic thrombocytopenic purpura receive plasma exchange as
for patients with thrombocytopenic purpura without systemic lupus. (2D)
12.11: Systemic lupus and pregnancy
12.11.1: We suggest that women be counseled to delay pregnancy until a complete remission of LN has been achieved. (2D)
12.11.2: We recommend that CYC, MMF, ACE-I, and ARBs not be used during pregnancy. (1A)
12.11.3: We suggest that hydroxychloroquine be continued during pregnancy. (2B)
12.11.4: We recommend that LN patients who become pregnant while being treated with MMF be switched to azathioprine (1B).
12.11.5: We recommend that, if LN patients relapse during pregnancy, they receive treatment with corticosteroids, and
depending on the severity of the relapse, azathioprine (1B).
12.11.6: If pregnant patients are receiving corticosteroids or azathioprine, we suggest that these drugs not be tapered during
pregnancy or for at least 3 months after delivery. (2D)
12.11.7: We suggest administration of low-dose aspirin during pregnancy to decrease the risk of fetal loss. (2C)
12.12: LN in children
12.12.1: We suggest that children with LN receive the same therapies as adults with LN, with dosing based on patient size and
GFR. (2D)
Chapter 13: Pauci-immune focal and segmental necrotizing GN
13.1: Initial treatment of pauci-immune focal and segmental necrotizing GN
13.1.1: We recommend that CYC and corticosteroids be used as initial treatment. (1A)
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13.1.2: We recommend that rituximab and corticosteroids be used as an alternative initial treatment in patients without
severe disease or in whom CYC is contraindicated (1B).
13.2: Special patient populations
13.2.1: We recommend the addition of plasmapheresis for patients requiring dialysis or with rapidly increasing SCr. (1C)
13.2.2: We suggest the addition of plasmapheresis for patients with diffuse pulmonary hemorrhage. (2C)
13.2.3: We suggest the addition of plasmapheresis for patients with overlap syndrome of ANCA vasculitis and anti-GBM GN,
according to proposed criteria and regimen for anti-GBM GN (see Chapter 14; 2D).
13.2.4: We suggest discontinuing CYC therapy after 3 months in patients who remain dialysisdependent and who do not have
any extrarenal manifestations of disease. (2C)
13.3: Maintenance therapy
13.3.1: We recommend maintenance therapy in patients who have achieved remission (1B).
13.3.2: We suggest continuing maintenance therapy for at least 18 months in patients who remain in complete remission.
(2D)
13.3.3: We recommend no maintenance therapy in patients who are dialysis-dependent and have no extrarenal manifestations
of disease. (1C)
13.4: Choice of agent for maintenance therapy
13.4.1: We recommend azathioprine 1–2 mg/kg/day orally as maintenance therapy (1B).
13.4.2: We suggest that MMF, up to 1 g twice daily, be used for maintenance therapy in patients who are allergic to, or
intolerant of, azathioprine. (2C)
13.4.3: We suggest trimethoprim–sulfamethoxazole as an adjunct to maintenance therapy in patients with upper respiratory
tract disease. (2B)
13.4.4: We suggest methotrexate (initially 0.3mg/kg/week, maximum 25 mg/week) for maintenance therapy in patients
intolerant to azathioprine and MMF, but not if GFR is 60ml/min per 1.73m2. (1C)
13.4.5: We recommend not using etanercept as adjunctive therapy. (1A)
13.5: Treatment of relapse
13.5.1: We recommend treating patients with severe relapse of ANCA vasculitis (life- or organ-threatening), according to the
same guidelines as for the initial therapy (see Section 13.1; 1C).
13.5.2: We suggest treating other relapses of ANCA vasculitis by reinstituting immunosuppressive therapy or increasing its
intensity with agents other than CYC, including instituting or increasing dose of corticosteroids, with or without
azathioprine or MMF. (2C)
13.6: Treatment of resistant disease
13.6.1: In ANCA GN resistant to induction therapy with CYC and corticosteroids, we recommend the addition of rituximab
(1C), and suggest i.v. Ig (2C) or plasmapheresis (2D) as alternatives.
13.7: Monitoring
13.7.1: We suggest not changing immunosuppression based on changes in ANCA titer alone. (2D)
13.8: Transplantation
13.8.1: We recommend delaying transplantation until patients are in complete extrarenal remission for 12 months. (1C)
13.8.2: We recommend not delaying transplantation for patients who are in complete remission but are still ANCA-positive. (1C)
Chapter 14: Treatment of anti-glomerular basement membrane antibody GN
14.1: Treatment of anti-GBM GN
14.1.1: We recommend initiating immunosuppression with CYC and corticosteroids plus plasmapheresis (see Table 31) in all
patients with anti-GBM GN, except those who are dialysis-dependent at presentation and have 100% crescents in an
adequate biopsy sample, and do not have pulmonary hemorrhage. (1B)
14.1.2: Start treatment for anti-GBM GN without delay once the diagnosis is confirmed. If the diagnosis is highly suspected, it
would be appropriate to begin high-dose corticosteroids and plasmapheresis (Table 31) while waiting for confirmation
(Not Graded).
14.1.3: We recommend no maintenance immunosuppressive therapy for anti-GBM GN. (1D)
14.1.4: Defer kidney transplantation after anti-GBM GN until anti-GBM antibodies have been undetectable for a minimum
of 6 months (Not Graded).
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